The increasing incidence of dysbiosis and its pathogenic consequences naturally raises questions about the search for treatment and prevention.
It is established that in the pathogenesis of non-infectious colitis the decisive role is played by dysbiosis, that is, the reduction of the level of probiotic bacteria and the increase in the number of conditionally pathogenic species, especially their virulent strains. Under the conditions of functioning of the normal microbial composition of the microbiome, the probiotic bacteria exert a suppressive effect on the conditionally pathogenic microflora.
It is important that even with the development of dysbiosis only the ratio of the two groups of microorganisms changes, and, for example, the biotic bacteria do not completely disappear, which makes it possible to restore them.
The results of many years of experimental studies carried out in the laboratory of Professor AP Levitsky showed the antidysbiotic property of polyphenolic compounds, in particular bioflavonoids. It is known that bioflavonoids belong to plant substances and have a very wide range of biological effects: antioxidant, anti-enzyme, membrane-protecting, hepatoprotective, anti-dysbiotic, anti-inflammatory and therefore used for the treatment of many diseases, in the first place.

dysbiosis; colitis; probiotics; prevention

Age features of colon dysbiosis / L. V. Kataev, K. B. Stepanova, T. F. Stepanova [and others]. ZhMEI. 2010. No 1. S. 76-80.

Khodosevich AG Biocenosis of the large intestine in patients with chronic hepatitis and cirrhosis and the possibility of its correction. Practical medicine. 1997. № 5-6. Pp. 44-47.

Microbiocenosis of the parietal mucin of the gastrointestinal tract of rats with induced dysbiosis / Yu. V. Nesvizhsky, EA Bogdanova, VV Zverev [et al.]. ZhMEI. 2007. No 3. S. 57-60.

Danilova AA, Petrov SA Influence of extreme states on the activity of aminotransferases when used in the composition of diets immobilized on high carbohydrate carriers of probiotic microorganisms. Odessa Medical Journal. 2013. No. 1 (135). Pp. 17-20.

A single endotoxin aggression causes a dose-dependent reversible activity of rat liver ITO cells without their transdifferentiation into myofibroblasts / I. M. Salakhov, A. S. Sozinov, S. R. Abdulkhakov [et al.]. BABIM. 2000.V. 130, No. 10. P. 449-452.

Krylov V.P., Orlov V.T., Malysheva T.V. Principles of combination therapy of intestinal dysbiosis. ZhMEI. 1998. No. 4. P. 64-66.

Levitsky A.P. Dental endotoxinemia. Journal of the National Academy of Medical Sciences of Ukraine. 2013.V. 19, No. 4. P. 490–493.

Comparative characteristics of intestinal microbiocenosis in patients with irritable bowel syndrome and non-specific ulcerative colitis / VI Vdovichenko, OP Korniychuk, OO Merentsova [et al. Modern gastroenterology. 2010. No. 4 (54). Pp. 67-70.

Zaitseva NE, Sapa IY Basics of application of microbiological therapy in clinical practice. Clinical immunology. Allergology. Infectology. 2007. № 3. S. 49-52.

The rational choice of a probiotic in the practice of a gastroenterologist. Russian Medical Bulletin. 2007.V. 12, No. 4. P. 46-48.

The effect of Lactobacillus rhamnosus on enterohemorrhagic Escherichia coli infection of human intestinal cells in vitro / J. Hirono, T. Yoshida, T. Sugiyama [et al.]. Microbiol. and Immunol. 2003. v. 47, № 6. P. 405-409.

Prospects for the use of probiotics in pediatric practice / L.N. Mazankova, N.O. Ilyina, L.V. Begiashvili [et al.]. Questions of practical pediatrics. 2008. No. 2. P. 76-80.

Alvarez-Olmos M. I., Oberhelman R. A. Probiotic agents and infections diseases: A modern perspective on a traditional therapy. Clin. Infec. Diseases. 2001. 32, № 11. P. 1567-1576.

Ivashkina N. Yu., Botina S. G. Original domestic probiotic acipol: molecular biological and metabolic characteristics. RZHGGK. 2009. No 2. S. 58-64.

Immunobiological preparations. Directory / VV Smirnov, OP Selnikov, VD Dumansky [and others]. K .: Molior, 2001. 192 p.

Usenko D.V., Gorelov A.V., Bitneva R. L. The use of a new synbiotic in the treatment of intestinal infections in children. Nutrition issues. 2007.V. 76, No. 1. P. 70-75.

Loboda VF, Shulgai OM, Kinash MI Application of the Symbiter probiotic for the correction of gastrointestinal disorders in infants. Bulletin of scientific research. 2009. № 1. S. 37-39.

Probiotics in the treatment of acute intestinal infections in children / S. V. Moskalenko, S. B. Solomko, V. M. Kuznetsov [et al.]. Clinical immunology. Allergology. Infectology. 2007. No 1. S. 73-74.

Gervais Donone – Method and composition for treatment of infant diarrhea / E. Postaire, C. Bouly, C. Gueria-Danan [et al.]. Пат. 6399055 СШАб МПК7 A01N 63/00, C12N 1/10. № 09/179179, заявл. 27.10.98. Опубл. 04.06.02. НПК 424/93.45.

Sarkar S., Misra A. K. Effect of feeding dietetic yoghurt on the nutritional status and excretory pattern in rats and infants. Egypt. J. Dairy Sci. 2002. 30, № 1. P. 63-73.

Survival of yougurt bacteria in the human gut / M. Elli, M. L. Callegari, S. Ferrari [et al.]. Appl. and Environ. Microbiol. 2016. v. 72, № 7. P. 5113-5117.

Safronova L.A., Osadchaya A.I., Ilyash V.M. Synbiotics: prospects for the creation of bacteria of the genus Bacillus and lactitol. Likarska on the right. Medical business. 2007. No. 4. P. 3-8.

Blinkova L. P. bacteriocins: criteria, classification, properties, detection methods. ZhMEI. 2003. No. 3. S. 109-119.

Vakhitov T. Ya., Petrov L.N., Bondarenko V. M. The concept of a probiotic preparation containing original microbial metabolites. ZhMEI. 2005. No 5. S. 108-114.

Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth / F. Yan, H. Cao, T. L. Cover [et al.]. Gastroenterology. 2007. v. 132, № 2. P. 562-575.

Fructooligosaccharides – occurrence, preparation, and application / J. W. Yun [et al.]. Enzyme and Microbial Technology. 1996. v. 19. P. 107-117.

Roberfroid M. B., Delzenne N. Dietary fructans. Annual Review of Nutrition. 1998. v. 18. P. 117-143.

Inulin and oligofructose as dietary fiber: A review of the evidence // G. Flamm, W. Glinsmann, D. Kritchevsky [et al.]. Cret. Rev. Food Sci. and Nutr. 2001. v. 41, № 5. P. 353-362.

Levitsky A.P. Inulin - food for bacteria, medicine for people. Odessa: KP OGT, 2003.28 p.

Levitsky AP, Tsiselsky Yu. V. Use of prebiotics for the prevention and treatment of patients with diabetes mellitus: guidelines. K .: MOZU, NAMNU, 2010. 20 p.

Levitsky A.P., Stefanov A.V. Methods for determining the activity of elastase and its inhibitors: guidelines. K .: State Pharmacological Center, 2002.15 s.

Levitsky A. P. Polyphenolic substances as regulators of microbial homeostasis. News of dentistry. 2008. No. 4. S. 19-21.

Makarenko O., Levitsky A. Biochemical mechanisms of therapeutic and prophylactic effects of bioflavonoids. Journal Pharmacy and Pharmacology. 2016. v. 4, № 8 P. 451-456.

A human volunteer study to determine prebiotic effects of lactulose powder on human colonic microbiota / K. M. Tuohy, C. J. Ziemer, A. Klinder [et al.]. Microbial Ecology in Health and Disease. 2002. v. 14. P. 165-173.